Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy
Agent Molecular targets Phase (comparator) Patient population Clinical activity in RCC References Tivozanib (AV-951) VEGFR-1, 2, 3 Phase III (TIVO-1) (vs. sorafenib) Clear cell RCC PFS (11.9 vs. 9.1 mo)…